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The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or
coronavirus disease 2019 (COVID-19) in China, which spread to the rest of the world, led
the World Health Organization to classify it as a global pandemic. COVID-19 belongs to
the Bettacoronavirus genus of the Coronaviridae family, and it mainly spreads through the
respiratory tract. Studies have now confirmed a human-to-human transmission as the
primary pathway of spread. COVID-19 patients with a history of diseases such as
respiratory system diseases, immune deficiency, diabetes, cardiovascular disease, and
cancer are prone to adverse events (admission to the intensive care unit requiring invasive
ventilation or even death). The current focus has been on the development of novel
therapeutics, including antivirals, monoclonal antibodies, and vaccines. However,
although there is undoubtedly an urgent need to identify effective treatment options
against infection with COVID-19, it is equally important to clarify management protocols
for the other significant diseases from which these patients may suffer, including cancer.
This review summarizes the current evidence regarding the epidemiology, pathogenesis,
and management of patients with COVID-19. It also aims to provide the reader with
insights into COVID-19 in pregnant patients and those with cancer, outlining necessary
precautions relevant to cancer patients. Finally, we provide the available evidence on the
latest potent antiviral drugs and vaccines of COVID-19 and the ongoing drug trials.
Keywords: cancer, coronavirus disease 2019, coronavirus disease, severe acute respiratory syndrome coronavirus
2, severe acute respiratory syndromeOctober 2020 | Volume 10 | Article 5723291
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Coronaviruses (CoVs) are a family of single-stranded positive-sense
RNA viruses that infect humans and many animal species,
including bats, civet cats, raccoon dogs, macaques, ferrets, pigs,
Himalayan palm civets, livestock, birds, and mice (1–3). The
pathologies stemming from CoVs predominantly damage the
respiratory, central nervous, intestinal, and hepatic systems (4).
CoVs have the largest genome size among RNA viruses and are
subdivided into four genera: Alpha, Beta, Gamma, and
Deltacoronavirus. Until 2003, it was imagined that only two CoVs
(HCoV-229E and HCoV-OC43) were responsible for infections of
the upper respiratory tract, ranging in respiratory symptoms such as
the common cold, pneumonia, and bronchiolitis, but many
researchers suspected that there existed more than two HCoVs (5,
6) (Figure 1). Unexpectedly, a widespread epidemic of the severe
acute respiratory syndrome coronavirus (SARS-CoV-1) broke out
between November 2002 and September 2003 that originated in
Foshan, Guangdong province, China (7). The SARS-CoV-1 is an
extremely pathogenic virus with an overall fatality rate of around
10%, reaching more than 8,000 human infections spanning 29
different countries (8). The SARS-CoV-1 is very contagious and
displays influenza-like symptoms, including high fever, myalgia,
dyspnea, lymphopenia, and pneumonia (9). The organization of the
SARS-CoV-1 genome (29,740 bases long, positive-stranded RNA) is
similar to that of other CoVs (10). The World Health Organization
(WHO) declared the SARS epidemic to be contained on July 5,
2003, and since then, no SARS outbreaks were reported. Then, inFrontiers in Oncology | www.frontiersin.org 22012, the Middle East respiratory syndrome-related coronavirus
(MERS-CoV) emerged and became the second most pathogenic
member of the Coronaviridae family in humans in the 21st century.
MERS-CoV was first identified in sputum samples of a man in
Saudi Arabia admitted with pneumonia (11). Camels were later
identified as the cause of spillover to humans and caused the high
case-fatality rates in humans across the globe, spanning 27 countries
(12). Between 2012 and 2017, WHO reported nearly 2,494
confirmed cases of MERS-CoV infection with at least 858 deaths,
the majority from Saudi Arabia. In December 2019, the WHO was
informed of cases of pneumonia of unknown cause in Wuhan,
China—the third spillover of an animal coronavirus to humans
(13). This newly emerged CoV, adopted as SARS-CoV-2 was
identified as the cause of a cluster of upper respiratory tract
infections or so-called coronavirus disease 2019 (COVID-19),
which rapidly emerged in China and rapidly spread to all
countries on the globe (13, 14). The WHO declared this rapid
escalation of COVID-19 a pandemic in March 2020 and cases
continue to rise all over the world, triggering a devastating global
health crisis. This review summarizes our current knowledge about
the epidemiology, pathogenesis, diagnosis options, and the latest
developments in potent antiviral drugs and vaccines for COVID-19.EPIDEMIOLOGY
CoVs have been present in humans and various animal species
on the planet for hundreds of years, but their exact originFIGURE 1 | The timeline of the emerging coronavirus. The origin of the history of coronaviruses is pinpointed in the 1930s, when the avian infectious bronchitis (IBV)
was first detected in humans. The progression and development of coronaviruses continued to the 1940s (detection of murine hepatitis virus and transmissible
gastroenteritis virus), the 1960s (detection of HCoV-B814, HCoV-229E, and HCoV-OC43), 2003 (detection of SARS-CoV or SARS-CoV-1), 2004 (detection of
HCoV-NL63), 2005 (detection of HCoV-HKU1), 2012 (detection of MERS), and 2019 (detection of SARS-CoV-2).October 2020 | Volume 10 | Article 572329
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Betacoronavirus genus, and after SARS-CoV-1 (in 2003) and
MERS-CoV (in 2015), it is the third major zoonotic coronavirus
disease (15). CoVs are a large cluster of single-stranded RNA
viruses that can be isolated from different animal species.
Phylogenetic and serological studies pinpoint that SARS-CoV-
1 and MERS-CoV were a result of a spillover from a wildlife
reservoir. Dromedary camels (Camelus dromedarius) are now
known to be the vertebrate animal reservoir that intermittently
transmits the MERS-CoV to humans (16). The outbreak of
SARS-CoV-2 originated in Wuhan, China, supposedly from a
wildlife market, and the sale of wild animals might be the source
of this zoonotic infection (17). The intermediate host for SARS-
CoV-2 is currently unknown. Research data suggest that bats
(RaTG13) and pangolins carried CoV, thus making them the
proximal source of SARS-CoV-2. Accumulating phylogenetic
evidence indicates several horseshoe bat species of the genus
Rhinolophus within the family Rhinolophidae as a common
reservoir for SARS-CoV-1, MERS-CoV, and now SARS-CoV-2
(18, 19). Although RaTG13, sampled from a Rhinolophus affinis
bat, is ~96% overall identical to SARS-CoV-2, its spike diverges
in the receptor-binding domain (RBD), which suggests that it
may not bind efficiently to human angiotensin-converting
enzyme 2 (ACE2) (20). Also, evidence from metagenomic
sequencing identified various lineages of Malayan pangolins
(Manis javanica) coronavirus (Pangolin-CoV) with 92.22%
identity to SARS-CoV-2, suggesting pangolins as another
possible intermediate host in the outbreak of COVID-19.
However, more detailed studies involving pangolin- (Manis
javanica) and bat- (Rhinolophus affinis) related CoV (21) areFrontiers in Oncology | www.frontiersin.org 3necessary. As of August 5, 2020, a total of 18,445,787 confirmed
cases globally with 691,740 deaths had been reported by WHO,
and the number is increasing. The United States, with more than
4,850,114 confirmed cases and 159,128 deaths; followed by Brazil
(2,808,076 cases, 96,096 deaths); and India (1,908,254 cases,
39,796 deaths) are the three countries with the highest
occurrence of COVID-19 (22). Currently, there is no medicine
or preventive therapy for COVID-19, and controlling the
contagion is the only preventive option to thwart the spread of
COVID-19 (23).EVOLUTIONARY RELATIONSHIPS OF
SARS-COV-2
Sequences most similar to the SARS-CoV-2 cDNA sequence
were found using the BLASTn online tool (24). The evolutionary
history was derived using the neighbor-joining method (25). The
optimal tree with the sum of branch length = 1.11522020 is
shown in Figure 2. The evolutionary distances were analyzed
using the maximum composite likelihood method (26) and are in
the units of the number of base substitutions per site. The
proportion of sites where at least one unambiguous base is
present in at least one sequence for each descendent clade is
shown next to each internal node in the tree. This analysis
involved 10 nucleotide sequences. Codon positions included
were 1st+2nd+3rd+Noncoding. All ambiguous positions were
removed for each sequence pair (pairwise deletion option). There
was a total of 32,687 positions in the final data set. Evolutionary
analyses of SARS-CoV-2 were conducted in MEGA X (27). TheFIGURE 2 | Evolutionary analysis of SARS-CoV-2. The analysis demonstrates that the main similar species to SARS-CoV-2 is bat coronavirus RaTG13.October 2020 | Volume 10 | Article 572329
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coronavirus most similar to SARS-CoV-2 is bat coronavirus
RaTG13, and these viruses have the most homology with
pangolin coronavirus (MP789). Therefore, it could be
concluded that the main origin of SARS-CoV-2 might be due
to bats or pangolins. However, the issue of which organism is
initially responsible for carrying and transmitting this novel
coronavirus to humans has not been thoroughly analyzed.PATHOGENESIS
Recent studies revealed that the genome sequence of SARS-CoV-2
is very similar to that of SARS-CoV-1 and MERS-CoV, therefore
serving as models to delineate the pathogenesis of COVID-19 (28).
The CoVs encode for several structural and nonstructural proteins
required to generate a complete virion. CoVs particles have a
variety of packaged host-encoded proteins, including enzymes
such as protein kinases cyclophilin A, and apolipoprotein B
mRNA editing enzyme, catalytic polypeptide-like 3G
(APOBEC3G) that may have critical roles in increasing or
inhibiting infection (29). CoVs encode four conserved proteins
that are incorporated into the virion: spike (S), envelope (E),
membrane (M), and nucleocapsid (N) (30) (Figure 3). Studies on
SARS-CoV-1 reveal that the S protein, encoded by the first open
reading frame (ORF) downstream of the replicase gene, is
conserved in all CoVs (31, 32). The S protein is a 180 kDa
protein that plays a primary role in attachment and the entry
processes in the host organism’s cell. The first step of the infection
cycle of enveloped viruses is the interaction with cellular receptors
and subsequent fusion with the cell membrane, which is mediated
by spike protein (33, 34). The S protein contains an S1 subunit at
the N terminus and an S2 subunit at the C terminus; the S1
subunit contains an RBD that engages with the host cell receptor,
and the S2 domain contains the membrane fusion machine (30).
After the fusion, replication of viral RNA occurs in the hostFrontiers in Oncology | www.frontiersin.org 4cytoplasm by a unique mechanism in which RNA polymerase
binds to a leader sequence and then detaches and reattaches at
multiple locations, allowing for the production of a nested set of
mRNAmolecules with common 3’ ends. The antigen presentation
cells (APC) present their antigens as peptides to specific cytotoxic
T lymphocytes (CTLs) via major histocompatibility complex
(MHC, HLA in humans) (35). The antigen presentation of
SARS-CoV-1 mainly depends on MHC I molecules, but MHC
II also helps its presentation. Subsequently, antigen presentation
stimulates humoral- and cellular immunity. IgM and IgG are the
main antibodies against the SARS-CoV-1 (36). The IgM
antibodies disappear at the end of week 12 although the IgG
antibody can last longer. The IgG antibody plays a protective role
and is specific for spike and nucleocapsid antigens. A research
paper shows that the number of CD4+ and CD8+ T cells and
natural killer (NK) cells in the peripheral blood of COVID-19
patients are significantly decreased (37). The reduction of these
subsets results in the release of cytokines and pro-inflammatory
cytokines (IL-1b, IL-6, TNF-a), IFN-a, IFN-g, IL-12, IL-18, IL-33,
TGF-b, and chemokines (CCL2, CCL3, CCL5, CXCL8, etc.) (38).
The continuous production of these cytokines affects NK and CD8
T cells, leading to acute respiratory distress syndrome (ARDS),
which is considered the leading cause of death of COVID-19
patients (39).TRANSMISSION AND SYMPTOMS
COVID-19 spreads by human-to-human transmission through
droplet or direct contact, but the plausible interspecies
mechanism of the virus is not yet fully understood (40). When
exposed, the mean incubation period of 6.4 days until clinical signs
appear (2020) is confirmed. In models of the transmission process
of SARS-CoV-2, the reproduction number (R0) was predicted to be
in the range of 2.24 and 3.58 (the number of new infections
estimated to stem from a single case) depending on theFIGURE 3 | Structure of the SARS-CoV-2.October 2020 | Volume 10 | Article 572329
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with pneumonia caused by SARS-CoV-2, fever was the most
common symptom, followed by coughing. Although most
patients only experienced mild symptoms of the disease, some
patients experienced a rapid progression of their symptoms over a
week (42). Based on a meta-analysis of 1,994 patients with the
COVID-19 infection, Li et al. listed the most common symptoms in
order of frequency seen to be fever (88.5%), cough (68.6%), fatigue
(35.8%), phlegm or mucus from the throat or lungs (28.2%), and
dyspnea (21.9%), and dizziness (12.1%), diarrhea (4.8%), and
nausea and vomiting (3.9%) were less common (43) (Figure 4).
Growing evidence shows that SARS-CoV-2 infection is not limited
to the respiratory tract, and other organs may also be involved,
including the central nervous system (CNS) causing neurological
signs, including headache and nausea (43). Based on the evidence,
ACE2 is expressed in the brain, which makes the brain a potential
target of COVID-19. In a retrospective case study of 214
hospitalized patients with COVID-19 in Wuhan, China, more
than 36.4% of patients were found to have acute cerebrovascular
disease, disturbance of consciousness, and skeletal muscle damage
as well as neurological manifestations, such as dizziness, headache,
nausea, hypogeusia, and hyposmia (44). In another study, Helms
et al. enrolled 58 hospitalized patients (median age 63) with
COVID-19 and found that 69% of patients had agitation, 67%
corticospinal tract signs, and 36% a “dysexecutive” syndrome with
difficulty in concentration, attention, orientation, and following
commands (45). Specific clinical, diagnostic, and epidemiological
studies are needed to help define the manifestations and burden of
neurological disease caused by SARS-CoV-2.DIAGNOSIS
On routine blood tests, patients may present with an elevated
serum C-reactive protein (CRP), erythrocyte sedimentation rateFrontiers in Oncology | www.frontiersin.org 5(ESR), lactate dehydrogenase, creatinine, and prothrombin time
(46). The clinical diagnosis of COVID-19 is primarily based on
real-time quantitative polymerase chain reaction (RT-qPCR)
using a nasal swab, tracheal aspirate, or bronchoalveolar lavage
samples, and saliva samples. In addition, computed tomography
(CT) scan and identification of IgM/IgG by enzyme-linked
immunosorbent assay (ELISA) are other important diagnostic
tools (40). RT-qPCR is the most popular, useful, and direct
method for detecting SARS-CoV-2 in respiratory secretions and
blood. Previously, RT-qPCR also presented high sensitivity and
specificity for SARS-CoV-1 and MERS-CoV infection (47). Wang
et al. examined the sensitivity of the RT-qPCR assay in different
tissue samples. Bronchoalveolar lavage fluid specimens showed the
highest positive rates at 93% (n = 14) followed by sputum at 72%
(n = 75), nasal swabs at 63% (n = 5), fiber bronchoscope brush
biopsy at 46% (6/13), pharyngeal swabs at 32% (n =126), feces at
29% (n = 44), and blood at 1% (n = 3) (48). However, RT-qPCR
has some limitations, among which are a false-negative rate,
difficult nucleic acid detection protocols, and being time-
consuming (49). Many physicians proposed using the CT scan
of the chest as a primary method because of its high sensitivity
(50). In a meta-analysis, Xu et al. evaluated the effectiveness of
chest CT for COVID-19 diagnosis. The project included 16 studies
for a total of 3,186 patients. They divided the studies into two
groups based on the study site (Wuhan and other sites) and found
that the patients in Wuhan showed significant sensitivity in the
chest CT with the sensitivity values varying from 96% to 99%. In
regions other thanWuhan, the sensitivity varied from 61% to 98%.
However, the specificity was low (51). In a series of 51 patients (29
men and 22 women) in Taizhou, China, with chest CT and RT-
PCR assay performed within 3 days, the sensitivity of CT for
COVID-19 infection was 98% compared to the RT-PCR
sensitivity of 71% (p <.001) (51). Ai et al. compared the
diagnostic value of a chest CT scan with RT-qPCR assay in
COVID-19 Chinese patients. Although 59% (601 patients) had
positive RT-qPCR results, 88% (888 patients) had positive findingsFIGURE 4 | The main symptoms of COVID-19. There are a variety of symptoms reported by people infected by COVID-19 viruses, ranging from mild (yellow) to
severe illness (blue).October 2020 | Volume 10 | Article 572329
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IgM/IgG antibody detection tests are another tool for both
diagnosis and patient follow-up (53–55). In addition,
asymptomatic cases of COVID-19 showed CT abnormalities. It
is difficult to single out and study asymptomatic COVID-19
carriers because people usually get tested for the coronavirus
only if they suspect they may have it. Some people who appear
asymptomatic at first do later develop classic symptoms, such as
high temperatures, fatigue, and difficulty breathing. Long et al.
analyzed 37 asymptomatic cases through the contact tracing and
testing efforts in Wanzhou, China. The asymptomatic patients
were hospitalized for observation. Fifty-seven percent showed lung
abnormalities on a CT scan, and others presented with ground-
glass opacities: clear signs of inflammation in the lungs. Also, Inui
et al. evaluated the chest CT findings in cases from the cruise ship
“Diamond Princess” with COVID-19. Of 104 cases, 76 (73%) were
asymptomatic, 41 (54%) of which had lung opacities on CT.
Another 28 (27%) cases were symptomatic, 22 (79%) of which had
abnormal CT findings. Symptomatic cases showed lung opacities
and airway abnormalities on CT more frequently than
asymptomatic cases (56). It shows that even people with no
outward signs of infection could be experiencing some
temporary damage to their lungs (57).
The humoral immune system response to SARS-CoV-2 can
help to diagnose it. Detecting the production of antibodies,
especially IgM, which presents following the infection, can offer
an opportunity to enhance detection sensitivity and efficiency. IgM
and IgG antibodies appear in the blood at the end of the first week
after the manifestation of symptoms (58, 59). Guo et al. evaluated
serum IgA, IgM, and IgG responses in COVID-19. In their study,
IgA detection showed the highest sensitivity during about 4–25 days
after illness onset. The specific IgA reached the peak during 16–20
days after illness onset and then began to decline but remained at a
relatively high reading until 31–41 days. The median of RBD-
specific IgG was the lowest in early disease stages but increased at 15
days after the onset of the illness, reaching its peak 21–25 days after
the beginning of the illness, suggesting that IgG is quite efficient for
diagnostics at later stages. Although IgM reached its peak in the
early stages, the median of IgM was lower than that of IgA or IgG
(60). In both confirmed and suspect cases, the positive rates of IgM
antibodies were 75.6% and 93.1%, respectively. When the IgM
ELISA assay was combined with qRT-PCR, the sensitivity rate of
detection significantly increased (98.6%) (60). Recently, the U.S.
Food and Drug Administration (FDA) awarded emergency use
authorization (EUA) for Bodysphere’s SARS-CoV-2 IgG/IgM
Rapid Test Cassette that diagnoses COVID-19. The IgG/IgM
rapid test has a 91% specificity and 99% sensitivity rate and
detects antibodies in blood, serum, or plasma in 2 minutes to
recognize the current or past history of COVID-19. This test is
administered similarly to the blood glucose test (61).COVID-19 AND PREGNANCY
Data on the SARS-CoV-2 in pregnancy are limited, and there is
no evidence on transplacental transmission of this virus (62). SoFrontiers in Oncology | www.frontiersin.org 6far, the clinical symptoms of COVID-19-related pneumonia in
pregnant women have been the same as nonpregnant adult
patients (63). A total of 12 pregnancies had a mortality rate of
25% in the previous outbreak of SARS-CoV-1, owing to
complications such as ARDS (n=4), disseminated intravascular
coagulation (DIC) (n=3), acute renal failure (n=3), pneumonia
(n=2), and sepsis (n=2). In addition, assisted ventilation was
three times more likely to be needed among pregnant, compared
to nonpregnant, women. Among seven pregnant women that
were infected with SARS-CoV-1 in their first trimester, four
pregnancies ended in spontaneous abortion. For MERS-CoV, a
total of 13 cases reported in pregnant women were published.
Two pregnancies were asymptomatic, two pregnancies ended in
fetal death, two of them were born premature, and three patients
died (64). Two early reports describing 18 pregnancies with
COVID-19 showed that all were infected in the third trimester,
and clinical findings were the same as nonpregnant adults (65).
Fetal distress and preterm delivery were detected in many
COVID-19 patients. An intensive review describing 38
pregnant women infected with COVID-19 reveals that, unlike
SARS-CoV-1 and MERS-CoV, COVID-19 did not lead to
maternal deaths. Similarly to pregnant women infected with
SARS-CoV-1 and MERS-CoV, there was no confirmation of the
transmission of SARS-CoV-2 from mothers to their fetuses (66).
Chen et al. investigated clinical symptoms and possible in utero
transmission of SARS-CoV-2 in nine pregnant women. All nine
patients had a cesarean section in their third trimester. The
reported symptoms included fever (in seven patients), cough (in
four patients), myalgia (in three patients), sore throat (in two
patients), and malaise (in two patients). Although fetal distress
was observed in two cases, none of the mothers developed
pneumonia or died. It has been suggested that newborn infants
can be infected in other ways and not only in utero transmission.
Respiratory viral infections, such as SARS-CoV-2, can occur
postpartum through inhalation of the aerosolized agent
produced by coughing from the mother, relatives, healthcare
workers, or other sources in the hospital (52). It is essential to
remember that newborn infants can be infected in other ways
than in utero transmission, for example, after delivery through
the inhalation of the virus aerosols produced by coughing from
the infected mother, relatives, or healthcare workers or other
sources in the hospital (67). A recent case regarding a 17-day old
newborn diagnosed as COVID-19 who developed fever, cough,
and vomiting of milk was reported. In this household, the servant
was the earliest case; consequently, the mother was infected (68).
Shortness of breath, vomiting of milk, cough, and fever are so far
the most common symptoms reported in newborn babies (52).COVID-19 AND CANCER
It has been suggested that individuals older than 60 years and
those with a suppressed immune system are especially prone to
COVID-19. However, the data on COVID-19 in cancer patients
is only beginning to emerge (69, 70). A study from Wuhan
reported a higher frequency of COVID-19 in cancer patients asOctober 2020 | Volume 10 | Article 572329
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indicating that patients with cancer had a higher risk of severe
clinical events than those without cancer. The clinical
characteristics of SARS-CoV-2-infected cancer patients include
a median age of 65 years with lung cancer being the most
common (25%) associated malignancy. The symptoms are
similar to other COVID-19 patients, including fever (82.1%),
dry cough (81%), dyspnea (50.0%), and lymphopenia (82.1%).
The authors of that study opined that cancer patients show
poorer outcomes from the COVID-19 and should avoid
treatments causing immunosuppression (71). This thought is
echoed by other studies given that cancer patients infected with
SARS-CoV-2 had a significantly greater risk of needing
mechanical ventilation, intensive care unit (ICU) admission, or
of dying compared with general patients estimated at 3.5 times
greater than the general population (72). This was verified by
Liang et al., who evaluated 2,007 COVID-19 patients in a study.
They reported a significantly higher mortality rate or ICU
admissions in the cases in which the cancer patients required
mechanical ventilation (n=18) as compared to general patients
(39% vs. 8%; P = 0.0003) (73). Another important consideration
in COVID-19 patients with cancer is the timing of chemo- and
radiation therapy and the risks associated with their use.
Although cancer treatments may enhance the damaging effects
of the virus on the immune system with an increased risk of
death and other adverse events (hazard ratio (HR): 4.079, 95%
confidence interval (CI): 1.086–15.322, P = 0.037) (60), the lack
of treatment specifically aimed at cancer increases the risk of
death from the malignancy itself. It has been estimated that there
is a 16% enhanced risk of death for every month of delay of
radiotherapy in patients with head and neck cancer (HR: 1.16,
CI: 1.09–1.21) (74). Specific concerns include the use of immune
checkpoint inhibitors (ICIs) (75) and confusion in being able to
differentiate COVID-19 pneumonia from ICIs-induced
pneumonitis. The possible overlap between COVID-19-related
pneumonia and antiprogrammed cell death protein 1 (anti-PD-
1)/PD-L1-induced pneumonia as one of the adverse events of
these agents is the first concern. The overall incidence rate of
pneumonitis varies from 2.5% to 5% with PD-1/PD-L1 inhibitors
to 7%–10% with a dual combination of Cytotoxic T lymphocyte-
associated antigen-4 (CTLA-4)/PD-1 inhibitors (76).
Pneumonitis is the most deadly adverse event associated with
PD-1/PD-L1 inhibitors with an estimated 35% of treatment-
related deaths (77). The second concern is the possible adverse
effect of cytokine storm-related to PD-1 inhibitors on the
pathogenesis of COVID-19. As described above, the cytokine
storm is a common phenomenon of immune hyperactivation in
COVID-19 pathogenesis (78). On the balance, it appears that the
risks of treating cancer carry a far greater risk of complications
than avoiding them. Temporary delay of anticancer therapy in
COVID-19 patients who are on long-term disease control with
chemotherapy or ICIs may seem prudent until the availability of
more robust data (60). To address this critical issue, institutions
must continuously analyze and update their clinical policy for
dealing with COVID-19 in cancer patients in the light of
emerging evidence in literature (79, 80). Other ancillary actionsFrontiers in Oncology | www.frontiersin.org 7include reducing unnecessary clinic appointments and shifting to
telemedicine to improve communication between patients and
healthcare workers (81, 82). In Table 1, we summarize several
considerations and decisions according to the society of surgical
oncology (SSO) opinions.PREVENTION
To help prevent the spread of COVID-19, hands should be
washed often, either with soap and water for 20 seconds or a
hand sanitizer that contains at least 60% alcohol. There must be a
distance between people, and mouth and nose must be covered
with a cloth face cover when around others. Until now, there is
no vaccine or particular medicine available against SARS-CoV-2.
The only intervention strategy is the control of transmission that
the majority of countries have activated. The extensive measures
to decrease person-to-person transmission of SARS-CoV-2
include isolation, mandatory quarantine strategies of high-
incident cities and countries, social distancing, and community
containment measures (91).POTENTIAL INTERVENTIONS
STRATEGIES FOR COVID-19
The expectancy for vaccines against SARS-CoV-2 has urged
scientists to find alternative methods to control COVID-19.
Now, clinical trials are investigating the possible effect of
therapeutic agents on COVID-19. Some of them are listed in
Table 2.
Interferons
New therapeutic interventions will likely require a long lead time
for the development of approved drugs. Thus, in light of the dire
need and urgency to identify the treatment and control of
COVID-2019, a repurposing of IFNs and other approved drugs
is a potential option in control of COVID-19 infection. Based on
previous studies, SARS-CoV-1 and MERS-CoV are valuable for
determining the suitability of IFN-I as a treatment strategy in
COVID-19. Pei et al. showed that oral administration of IFN-a
inhibited the replication of chicken and human CoVs (92, 93). In
addition, Morgenstern B et al. showed that IFN-b in
combination with Ribavirin inhibited the replication of SARS
in human and animal cell lines (94). In vitro studies have already
demonstrated that SARS-CoV-2 has greater sensitivity to IFN-I
compared with SARS-CoV-1 studies on SARS-CoV-1 and
MERS-CoV (95). The vapor inhalation of IFN-a in
conjunction with ribavirin is a guideline in China for the
treatment of COVID-19 (96). Treatment with IFN-a or IFN-b
at a concentration of 50 international units (IU) per milliliter
reduces viral titers by 3.4 logs or over 4 logs, respectively, in Vero
cells (97). IFN a and g, alone or in combination, showed partial
efficacy against the animal coronaviruses as well as inhibiting
SARS-CoV-1 replication in vitro. IFN b had the highest potency,October 2020 | Volume 10 | Article 572329
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post-infection (98). Zhou et al. studied 77 COVID-19 patients in
Wuhan, China, who were treated with nebulized IFN-a2b,
arbidol, or a combination of the two. The result showed that
the IFN-a2b therapy significantly reduced the duration of the
detectable virus and inflammatory markers, IL-6, and CRP (99).
In a mouse model of MERS-CoV infection, although treatment
with IFN-b in combination with lopinavir-ritonavir did not
significantly reduce lung pathology, it improved pulmonary
function (100). Collectively, data suggested that interferons
(IFN-a and IFN-b) could be a possible answer against
COVID-19 therapy (101).
Intravenous Gammaglobulin
Intravenous gammaglobulin (IVIg) is a pool of IgG prepared
from serum and primarily used for patients with antibody
deficiencies that might be effective against CoVs (102). During
the outbreak of SARS-CoV-1, patients in Singapore used IVIg
widely. Initiation of IVIg as adjuvant treatment for COVID-19
pneumonia within 48 hours of admission to the ICU can reduce
the use of mechanical ventilation, hospital length of stay, and
length of stay in the ICU. The rationale for the use of IVIG inFrontiers in Oncology | www.frontiersin.org 8SARS-CoV-2 infection is the modulation of inflammation. Cao
et al. evaluated IVIg usage in three SARS-CoV-2 patients in
China. All three patients were classified as severe, and all had
lymphopenia with elevated inflammatory markers. The patients
received IVIg at 0.3–0.4 g/kg/day for 5 days. After 2 days, they all
had normalization of temperature, and after 5 days of treatment
with IVIg, their respiratory symptoms were alleviated. However,
this study has some limitations including the concurrent usage of
antivirals in two of the three patients and steroids in one patient
and the lack of controls (103). In addition, IVIg reduced the 28-
day mortality of patients with severe COVID-19 pneumonia
(104). In a case report, Lanza et al. reported the successful
outcome of IVIg treatment in a 42-year-old Caucasian woman
with COVID-19. IVIg was begun, specifically 450 mL (5 mL/kg)
at 36 mL/h x 3 days with premedication with antihistamine and
rehydration. The patient was discharged after 15 days with two
negative swabs and reduced inflammatory markers,
normalization of liver function, and recovery of lung function
(105). The IVIg would be more beneficial if the immune IgG
antibodies were collected from patients who have recovered from
COVID-19 in the same city or the surrounding area to increase
the chance of neutralizing the virus (106). However, manyTABLE 1 | Therapeutic considerations of several cancers during the SARS-CoV-2 pandemic.
Type of cancer Therapeutic considerations or decisions Reference
Breast cancer Ductal Carcinoma in-situ:
Defer surgery for 3–5 months.
Treat estrogen receptor (ER) + ductal carcinoma in situ (DCIS) with endocrine therapy.
Triple-Negative/HER2+ Invasive:
Use of NAC as treatment, Emergency surgery must be performed
(83)
Colorectal cancer Defer surgery. Proceed with curative intent surgery for non-metastatic patients, for rectal cancer, NAC plus radiation (5 × 5 Gy) (84)
Thyroid cancer A severe form of Graves’ disease that does not respond to therapy should urgently be operated. Patients with severe Goiter should
urgently be operated.
(85)




Symptomatic small bowel neuroendocrine tumors and tumors with significant growth or short doubling times should urgently be
operated
Renal cancer cT1a lesions of renal cancer that are manageable with endoscopic resection should undergo endoscopic management, and cT1b
tumors should be respected. Patients completing NAC can stay on chemotherapy
Peritoneal surface
malignancy
The operation of patients with malignant bowel obstruction is possible. Defer CRS/HIPEC (an aggressive combination of surgery
and chemotherapy) for low-grade appendiceal mucinous neoplasms.
Consider NAC for peritoneal metastases from high-grade appendiceal cancer, gastric cancer, colorectal cancer, high-grade
mesothelioma, ovarian cancer, and desmoplastic small round cell tumors.
Lung cancer The duration of NAC for lung cancer patients with a low stage and better prognosis can be continued during the pandemic. For
patients with postoperative lymph node stage N2 with EGFR gene mutations, oral EGFR tyrosine kinase inhibitor (EGFR-TKI) as
NAC treatment may be considered a treatment option.
Patients with gene mutations including EGFR, anaplastic lymphoma kinase fusion (ALK), and ROS1 fusion, could benefit from




Urgently proceed with surgery in these conditions:
HPV-negative HNSCC (especially those with airway concerns).
HPV-positive HNSCC with significant disease burden or delay in diagnosis, and recurrent HNSCC.
Consider deferring> 30 days in following conditions: Low-risk PTC without metastasis and low-grade salivary carcinoma
(87)
Ovarian cancer Ovarian cancer patients who underwent chemotherapy are fragile. NAC should be favored even if primary cytoreduction surgery
could be envisaged.
For patients who must undergo the operation, continue the chemotherapy, and operation is suggested after six cycles of
chemotherapy.
(88)
Endometrial cancer Hysterectomy with bilateral adnexectomy associated with a sentinel lymph node procedure should be chosen. Defer surgery for 1
to 2 months in low-risk endometrial cancers. For high-risk patients combining PET-CT and sentinel lymph node biopsy is favored
(89)
Cervical cancer Defer diagnostic evaluations for 6–12 months.
Early-stage cervical cancer: proceed with the standard of care if it is possible. Defer radical trachelectomy or radical hysterectomy
for 6–8 weeks or until the pandemic resolves. In low-risk disease (<2 cm, low-risk histology) consider conization or simple
trachelectomy ± sentinel lymph nodes. In a gross visible tumor consider NAC
(90)October 2020 | Volume 10 | Article 572329
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thromboembolism, and it is prescription limited (107). Many
clinical and in vitro studies show that switching from IVIg to
subcutaneous immunoglobulin can minimize these adverse
events. However, the field lacks strong evidence to support the
use of IVIg for the treatment of CoVs, such as SARS-CoV-1,
SARS-CoV-2, and MERS (108).
Abelson Kinases (Abl1 and Abl2) Inhibitors
Potent inhibitors, such as Abelson kinase inhibitors (Abl1 and
Abl2), were previously tested against SARS-CoV-1 and MERS-
CoV (109). In mammals, there are two Abl kinases—Abl1 and
Abl2—that control different cellular processes, such as cell
survival and proliferation during development and homeostasis
(110). It has been shown that Abl2 is required for effective SARS-
CoV-1 and MERS-CoV replication in vitro. Recently, Coleman
CM et al. found that imatinib, an Abl kinase inhibitor, is a
possible inhibitor of both SARS-CoV-1 and MERS. They treated
Vero E6 (for SARS-CoV-1 and MERS-CoV), Calu-3 (for SARS-
CoV-1), and MRC5 (for MERS-CoV) cells with imatinib for
either the first 4 h of infection or 5 h after infection in a dose-
dependent manner. They found that the reproduction of these
viruses was significantly inhibited after treatment with imatinib
(109). Regarding SARS-CoV-2, upon binding of the virus spike
protein to ACE2, the action of proteases at the cell membrane
and in the endosomal compartment is required to complete the
subsequent fusion steps of the virus. Abl1 and Abl2 act on
proteases required for the completion of these steps by blockingFrontiers in Oncology | www.frontiersin.org 9their activity in SARS-CoV-2 (111). Collectively, the FDA-
approved Abl2 inhibitors imatinib and saracatinib should be
clinically tested for their antiviral effects in the early stage of
SARS-CoV-2 infection, either alone or in combination with
current antiviral drugs.
Antiviral Drugs
Remdesivir (GS-5734), as an adenosine nucleotide analog, was
developed by Gilead Sciences as a therapeutic agent for treating
RNA-based viruses that maintained global pandemic potentials,
including Ebola (EBOV) and the CoVs family viruses
exemplified by MERS-CoV and SARS-CoV-1 (112). With the
demonstration that remdesivir possessed broad activity against
RNA viruses, multiple groups assessed antiviral activity both in
vitro and in vivo in several studies validating its activity against
CoVs (113, 114). Warren et al. showed that remdesivir had
antiviral activity against MERS-CoV with an IC50 of 340 nM in
vitro (115). De Wit et al. tested the efficacy and antiviral activity
of animal models of MERS-CoV infection (116). Their results
showed that the treatment with remdesivir 24 h before
inoculation effectively inhibited MERS-CoV replication in
respiratory tissues and blocked the formation of lung lesions.
In vitro studies on cell cultures showed that the remdesivir has
half-maximum sufficient concentrations (EC50s) of 0.069 for
SARS and 0.074 mM for MERS (117). It may also be considered
for a broader range of CoVs, including SARS-CoV-2. A recent in
vitro study by Wang et al. assessed the antiviral activity of





Country Primary outcomes Secondary outcomes ClinicalTrials.gov
Identifier
hyperimmune plasma 49 Italy Mortality rate Time to extubating, length of intensive care unit
stays, Viral load, Immune response
NCT04321421
TCM prescriptions 340 China The disappearance rate of main symptoms,
Chest CT absorption
Virus antigen-negative conversion rate, Clinical





Resolution of fever, Percentage of patients
reporting each severity
Time to improvement in oxygenation, Mean
change in the 6-point ordinal scale
NCT04315298
Tocilizumab Injection 330 Italy One-month mortality rate Interleukin-6 level, Lymphocyte count, CRP, PaO2 NCT04317092
Sildenafil citrate
tablets
10 China Rate of disease remission, Rate of entering
the critical stage
Rate of no fever, rate of respiratory symptom







Viral load Time to clinical improvement (TTCI), Percentage of




3040 Spain Effectiveness of chemoprophylaxis The virological clearance rate, The mortality rate NCT04304053
Remdesivir 400 United
States
The proportion of Participants With
Normalization of Fever and Oxygen
Saturation










10 Colombia Viral Load, Change in IgG and IgM Intensive Care Unit Admission, Length of hospital





30 Iran Mortality changes in days 10 and 30,
Changes of CRP, IL-6, TNF-a, and PaO2/
FiO2 Ratio
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showed an IC50 of 770 nM and an IC90 equal to 1,760 nM
(118). Remdesivir is administered via an IV injection with an
initial dose on day 1 (200 mg in adults, adjusted for body weight
in pediatric patients) followed by a daily maintenance dose (100
mg in adults) for up to 10 days. Besides, remdesivir didn’t show
any serious side effects. Treatments that were approved by the
FDA have been assessed for antiviral activity against the COVID-
19 causative agent as well.
Lopinavir (LPV), as a protease inhibitor of human
immunodeficiency virus 1 (HIV-1) (119) is used in combination
with ritonavir (RTV) to increase the LPV half-life against SARS-
CoV-1 infection in patients and tissue culture. Deng L et al. assessed
Umifenovir (known as Arbidol) and LPV/RTV treatment for
patients with COVID-19 in comparison with LPV/RTV only. The
main aim of this study was to evaluate the conversion rate of
COVID-19 from the date of diagnosis (day 7, day 14) and assessed
whether the pneumonia was progressing or improving by chest CT
scan (day 7). After 7 days, the SARS-CoV-2 was not detected for 12
(75%) of 16 patients in the combination group compared with 6
(35%) of 17 in the LPV/RTV group (p<0.05). Also, after 2 weeks,
94% of patients in the combination group were cured compared to
52.9% in the LPV/RTV group (120).
Nelfinavir is another protease inhibitor used in the treatment
of HIV and AIDS (121). Yamamoto et al. showed that Nelfinavir
could significantly inhibit the replication of SARS-CoV-1.
Consequently, this antiviral drug could be an option for the
treatment of COVID-19 (122, 123).
Ribavirin is a guanosine analog that is another antiviral
treatment option against COVID-19. Although Ribavirin
mainly gained the FDA approval for the treatment of severe
respiratory syncytial virus (RSV) infection in children, it shows
activity against several RNA and DNA viruses (124). This drug is
used to treat several viral infections, including the hepatitis C
virus (HCV) and some viral hemorrhagic fevers. Khalid M et al.
investigated the efficacy of treatment with Ribavirin and IFN-a
in patients infected with MERS-CoV. A total of six patients were
enrolled in this study and treated with Ribavirin and IFN-a. The
authors declared that three patients after treatment had
successful outcomes, and Ribavirin and IFN-a therapy may
have effects in MERS-CoV patients (125).
Favipiravir is another drug under clinical development.
Favipiravir is a purine nucleoside analog, which acts as a
competitive inhibitor of RNA-dependent RNA polymerase
(126). Previously, it was demonstrated that favipiravir is
effective against influenza A and B and several agents of viral
hemorrhagic fever, such as Ebola (127, 128). An in vitro study
showed an effective activity of Favipiravir against SARS-CoV-2
(EC50 = 61.88 mM) (129). Cai et al. studied the activity of
favipiravir in 80 patients with COVID-19 in China. Patients with
mild or moderate COVID-19 were enrolled within 7 days from
disease onset. Thirty-five patients were assigned to favipiravir
and 45 patients to lopinavir/ritonavir. Patients received
favipiravir 1,600 mg orally twice daily on day 1 followed by
600 mg on days 2–14. Therapy continued until viral clearance,
up to a maximum of 14 days. They reported a significantFrontiers in Oncology | www.frontiersin.org 10reduction in the viral clearance of SARS-CoV-2 in patients
treated with favipiravir compared with historical controls
treated with lopinavir/ritonavir (4 days versus 11 days).
Furthermore, the rate of adverse events in patients receiving
favipiravir was significantly lower than lopinavir/ritonavir
(11.4% vs. 55.6%; P < 0.01) (130). Also, in a randomized
clinical trial, Chen et al. compared the efficacy and safety of
favipiravir versus umifenovir in the treatment of 240 patients
with COVID-19. The results showed that the 7-day clinical
recovery rate was 55.86% in the umifenovir group and 71.43%
in the favipiravir group (P = 0.01) (131).
Chemical Drugs
For decades, hydroxychloroquine (HCQ) and chloroquine were
used actively to treat infections with intracellular micro-
organisms such as malaria (132). Previously, the positive effect
of HCQ as a potent inhibitor of the most CoVs like SARS-CoV-1
was reported in several studies. In addition, chloroquine is
recognized to prevent viral infection by increasing the
endosomal pH required for virus/cell fusion, therefore
interfering with the glycosylation (118). Keyaerts and
colleagues evaluated the role of chloroquine in the inhibition
of SARS-CoV-1 infection in Vero E6 cells. Their result
demonstrated a significant decrease in the IC50 (the half-
maximal inhibitory concentration) of Chloroquine for antiviral
activity (8.8 ± 1.2 mM) versus its cytostatic activity (261.3 ± 14.5
mM) (133). Barnard, D et al. also examined the antiviral activity
of Chloroquine monophosphate and diphosphate in a BALB/C
mice model of SARS-CoV-1. They injected chloroquine (50 mg/
kg) intraperitoneally 4 hours before exposure to the virus. The
viral lung titers were 5.4 ± 0.5 to 4.4 ± 1.2 on day 3. In this study,
the EC50 of chloroquine, chloroquine monophosphate, and
chloroquine diphosphate were 1–4 mM, 4–6 mM, and 3–4 mM,
respectively (134). Now, clinical trials investigate the possible
effect of this agent against SARS-CoV-2 (135). Consequently, 20
clinical trials started in several hospitals in China. The first
results showed a significant effect of chloroquine in the
reduction of pneumonia, duration of symptoms, and viral
clearance compared with the treatment of the control group.
Although chloroquine failed to effectively treat mice infected
with the SARS-CoV-1, the inhibitory concentration of the
chloroquine for the SARS-CoV-2 was closer to 9 mM. This
may suggest that chloroquine could be more effective against
SARS-CoV-2 than SARS-CoV-1. Based on in vitro evidence and
still unpublished clinical experience, the panel recommended a
chloroquine phosphate tablet, at a dose of 500 mg twice per day
for 10 days, for patients diagnosed as mild, moderate, and severe
cases of SARS-CoV-2 pneumonia, provided that there were no
contraindications to the drug (136). Also, a study by Yao et al.
recommends an HCQ regimen of 400 mg twice a day for the first
day followed by 200 mg twice daily for the next 4 days (137). In a
recent survey, Wang et al. assessed the antiviral efficacy of five
FDA-approved agents including Ribavirin, Penciclovir,
Nitazoxanide, Nafamostat, Chloroquine, and 2 antiviral drugs
(Remdesivir and Favipiravir) in SARS-CoV-2-infected Vero E6
cells (118). The EC50 of Chloroquine in such Vero E6 cells wasOctober 2020 | Volume 10 | Article 572329
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that Remdesivir and Chloroquine are significantly effective in the
control of COVID-19 patients (118). Gautret et al. assessed
chloroquine with and without azithromycin and found that the
combination achieved a reduction in viral load (138). Huang
et al. conducted a clinical study to evaluate the efficacy and safety
of Chloroquine in hospitalized patients with COVID-19. A total
of 22 patients met the enrollment criteria. Patients were then
randomized into two groups: 10 patients were treated with
Chloroquine 500 mg orally twice daily for 10 days; 12 patients
were treated with Lopinavir/Ritonavir 400/100 mg orally twice
daily for 10 days. By Day 14, the incidence rate of lung
improvement based on CT imaging from the Chloroquine
group was more than double that of the Lopinavir/Ritonavir
group (rate ratio 2.21, 95% CI 0.81–6.62). These results suggest
that patients treated with Chloroquine appear to recover better
and regain their pulmonary function quicker than those treated
with Lopinavir/Ritonavir (137). Although the use of HCQ is
permitted by the FDA, wide use of HCQ has some side effects,
including serious cutaneous adverse reactions, fulminant hepatic
failure, and ventricular arrhythmias (139, 140).
ACE2 Analogs
The ACE2 has been recognized as an important receptor for the
SARS-CoV-2, and it has been suggested that inhibition of ACE2
might be used for the treatment of COVID-19 patients. Recently,
an international group of researchers in Spain, Canada, Austria,
and Sweden used human recombinant soluble ACE2 (hrsACE2)
to inhibit the infection of this novel life-threatening coronavirus
in a dose-dependent manner (138, 141). The SARS-CoV-2 virus
was isolated from a nasopharyngeal sample of a COVID-19
patient infected to Vero-E6 cells (cells used for SARS-CoV-2
isolation) with different titers of the virus. The viral RNA was
purified from the cells and examined by qRT-PCR. The results of
this study showed that the infection of cells in the presence of
hrsACE2 significantly prevented SARS-CoV-2 infections to
Vero-E6 cells. The hrsACE-2 was also capable of inhibiting
SARS-CoV-2 infections to human capillary and kidney
organoids (141).
Convalescent Plasma Transfusion Therapy
Another potential option is plasma therapy. Plasma provided
from the COVID-19 convalescents might make therapeutic
support available and can decrease the mortality rate of this
disease although official data of efficacy is still under investigation
(142). Moreover, a research paper published by Shen C et al.
evaluated the effects of convalescent plasma transfusion in the
treatment of 5 COVID-19 patients. All five patients received
antiviral agents and methylprednisolone at the time of treatment.
Patients received convalescent plasma transfusion with the
SARS-CoV-2 specific antibody (IgG) binding titer greater than
1:1,000, between 10 and 22 days after admission. Twelve days
after the transfusion, viral loads decreased and finally became
negative. The IgG and Nab titers increased as well. The ARDS
was also resolved in four patients, and three patients were
detached from mechanical ventilation within 14 days (143).Frontiers in Oncology | www.frontiersin.org 11Currently, several ongoing trials are investigating the safety
and efficacy of convalescent plasma transfusion as the
treatment for COVID-19.
Potential Vaccines
Effective vaccines are in the long term necessary to inhibit and
control SARS-CoV-2. Several types of vaccines that are based on
the S protein have been previously assessed. Previous studies on
SARS-CoV-1 suggest numerous vaccines using the full-length S
protein of MERS-CoV that could be beneficial against this new
pathogenic coronavirus, COVID-19 causative agent. Full-length
S protein-based vaccines are classified as viral vectors, DNA-
based vaccines, nanoparticle-based vaccines, virus-like particle
(VLP), recombinant S protein-based vaccines, and recombinant
RBD protein-based vaccines (144). Previous trials to produce
vaccines for CoVs that are pathogenic for humans have been
aimed at SARS-CoV-1 and MERS-CoV and have been tested in
animal models as well. However, no approved vaccine has been
introduced that is effective against MERS-CoV so far. Until
March 2020, there was one DNA-based vaccine against MERS-
CoV, which completed the phase I clinical trials in humans. In
this phase of the trial, Modjarrad K et al. considered the safety
and immunogenicity of a DNA vaccine against MERS-CoV. A
total of 75 participants were enrolled in the study and
intramuscularly received dose-escalation of 0·67 mg, 2 mg, or 6
mg GLS-5300 1 mL at baseline, week 4, and week 12. The authors
reported no vaccine-associated serious adverse events, and
immune responses were detected in more than 85% of
participants after 2-time vaccinations, suggesting further
development of the GLS-5300 as the anti-MERS-CoV vaccine
(145). Adenovirus vectors are widely applied for high-level
expression of proteins in mammalian cells and attract
increasing attention for their potential use as a live
recombinant vaccine and also as a transducing virus for use in
gene therapy (146). Currently, four viral vectored vaccines
including three adenoviral-vectored (ChAdOx1-MERS, BVRS-
GamVac, and adenovirus type 5 vector), and one modified
vaccinia virus Ankara (MVA) vectored (MVA-MERS-S) are in
progress against MERS-CoV and SARS-CoV-2 (147). Presently,
three clinical trials are investigating the safety and
immunogenicity of ChAdOx1 against MERS-CoV and SARS-
CoV-2 infections as well. The MERS001 study aims to assess the
safety and the immune responses of ChAdOx1 vaccination in
UK healthy volunteers (NCT03399578). In this phase I trial, a
total of 48 participants will be recruited, and five experimental
groups will receive a different dosage of the ChAdOx1 vaccine
intramuscularly. In a phase I/II randomized trial, the aim is to
determine the efficacy, safety, and immunogenicity of ChAdOx1
as the candidate SARS-CoV-2 vaccine (NCT04324606). A total
of 510 contributors will be divided into five groups and receive
ChAdOx1 (IM) and saline as the placebo. The primary endpoints
are the evaluation of the efficacy and safety, and secondary
endpoints are the evaluation of the efficacy, safety, tolerability,
and reactogenicity signs of ChAdOx1 for 7 and 28 days following
vaccination. Currently, 2 clinical trials are investigating the safety
and immunogenicity of MVA-MERS-S against MERS-CoVOctober 2020 | Volume 10 | Article 572329
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investigate the safety, reactogenicity, and immunogenicity of
recombinant adenovirus type 5 vector against SARS-CoV-2
infection. A total of 108 participants will be divided into 3
groups (low-dose, middle-dose, and high-dose groups) and
receive adenovirus type 5 vector (IM) in a dose-escalating
manner. The safety of the adenovirus type 5 vector is the
primary endpoint and the safety indexes of lab measures, the
immunogenicity indexes of the geometric mean titer of
the antibody, are some of the secondary endpoints. The LV-
SMENP-DC vaccine is another potential vaccine made by
adjusting dendritic cells (DCs) with lentivirus vectors (LVs)
expressing SMENP (an engineered synthetic minigene that
derives from the conserved domains of the viral structural
proteins and a polyprotein protease) of SARS-CoV-2 and
immune-modulatory genes. Cytotoxic T lymphocytes (CTLs)
will be activated through presenting specific antigens by LV-
DCs. A phase I/II study in China will be investigating the safety
and efficacy of the LV-SMENP-DC vaccine against the COVID-
19 causative agent. The primary endpoint of this study is
evaluation of safety and the second endpoint is to evaluate the
anti-COVID-19 efficacy of the LV-SMENP DC and antigen-
specific cytotoxic T cell vaccines (NCT04276896).
Candidate Antibodies
Neutralizing antibodies (Nabs) constitute a significant part of
protective immunity against viral infection in humans.
Monoclonal antibodies (mAbs) work in harmony to
target different antigenic domains on the viral surface
glycoprotein (148). Recognizing the mAbs becomes the first
important step toward a more extensive understanding of the
protecting antibody response and improving clinical methods
against COVID-19. The efficient treatment options against
SARS-CoV-2 can be achieved using specific neutralizing
monoclonal antibodies, including anti-SARS-CoV-2 neutralizing
mAbs, and anti-ACE2 monoclonal antibodies that can straight
prevent any stages of the viral life cycle or the receptor proteins
located on the host cell to prevent the virus attachment and entryFrontiers in Oncology | www.frontiersin.org 12(149). The SARS-CoV-2 infection begins with the interaction of
receptor-binding domains located on the S protein and target
receptors on the host cell surface, such as angiotensin-converting
enzyme 2 (ACE2) (150). The S protein plays a vital role in
coronavirus entry and inducing host immune response (151).
Consequently, it has been recognized as a key target to develop
effective mAbs against SARS-CoV-2 infection. The S1 subunit of S
protein has a receptor-binding motif placed in the RBD interacting
with the host cell receptor and mediates the virus attachment.
Neutralizing mAbs targeting the N-terminal and C-terminal of
such RBD, close to the junction of the S1 and S2 domains (152).
Since the emergence of MERS-CoV and SARS-CoV-1 outbreaks,
several mAbs were identified that showed encouraging outcomes
in vitro and in vivo that could be possibly useful against SARS-
CoV-2. Table 3 shows potential mAbs targeting MERS-CoV and
SARS-CoV-1 as well as their mechanism of action.CONCLUSION
SARS-CoV-2 is similar to the SARS-CoV-1 virus in its
pathogenicity, cl inical spectrum, and epidemiology.
Comparison of the genome sequences of SARS-CoV-2, SARS-
CoV-1, and the MERS-CoV show that SARS-CoV-2 has closer
sequence identity with SARS-CoV-1 compared to MERS CoV.
Although several animals, including pangolin (Manis javanica)
and bat (Rhinolophus affinis), have been hypothesized to be a
reservoir for COVID-19, no animal reservoir has yet been
confirmed. Studies suggest that ACE2 is the main human
receptor for COVID-19. The entry and spread of SARS-CoV-2
depend on the viral factors, including S protein and its S1 and S2
subunits, ACE2, viral load, viral titer, and viability of virus. Also,
the immune system factors, including genetics (such as HLA
genes), age, and gender all lead to whether an individual is
vulnerable to the SARS-CoV-2 infection, the duration and
severity of the disease, and the reinfection. SARS-CoV-2
appears to be more infectious than SARS-CoV-1 or MERS-







Disease Mechanism of action Reference
80R Phage display Mouse SARS-CoV-1 Binding to the S1 subunit (amino acid residues 426-492) and
blocking the interaction of S1 subunit with ACE2
(153)
CR3014 Phage display Ferret SARS-CoV-1 Binding to the amino acid residues 318-510 and 565 with high affinity on S1 subunit, blocking





Mouse SARS_CoV-1 Binding to epitopes overlapping with RBD and blocking the interaction of S1 subunit with
ACE2 in vitro
(155)
1A9 Phage display Mouse SARS_CoV-1 Binding to the Heptad repeat (HR) loops including HR1 and HR2 domain on S2 subunit and
blocking the interaction of the S2 subunit
(156)
MERS-4 Phage display Mouse MERS-CoV Binding to the C-terminal of the b5-b6, b6-b7, and b7-b8 loops on the receptor-binding
subdomain in RBD and blocking the interaction of S1 subunit with DPP4 in vitro
(157, 158)
MCA1 Phage display Mouse MERS-CoV Binding to RBD and blocking the interaction of S1 subunit DPP4 in vitro and in vivo (159)
G4 Phage display Mouse MERS-CoV Binding to the glycosylated surface on the S2 subunit in vitro. (160)
CDC2-C2 Phage display Mouse MERS-CoV Blocking the interaction of S1 subunit with DPP4 (161)October 2020 | Volume 10 | Article 572329
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or mild symptoms can spread viruses to others, which is
extremely challenging for preventing the spread of COVID-19.
The symptoms range from dry cough, sore throat, tiredness,
body aches, fatigue, nausea, vomiting, diarrhea, breathlessness,
pneumonia, ARDS, and multiple organ dysfunction leading to
death with case fatality rate ranging from 2% to 3% (162). Until
now, there is no vaccine or particular medicine available against
SARS.CoV-2. The only intervention strategy is the control of
transmission that the majority of countries have deployed.
Currently, several potent candidates for medications including
Nabs, previously discovered vaccines against SARS-CoV-1 and
MERS-CoV, and antiviral drugs against other viruses such as
Remdesivir, Favipiravir, and HCQ are under urgent investigation
in several countries worldwide. Finally, preventive vaccination is
highly recommended in light of the future prevention of
emerging coronavirus-related epidemics or pandemics.Frontiers in Oncology | www.frontiersin.org 13AUTHOR CONTRIBUTIONS
OK, the first author of the manuscript, collected the data and
wrote the primary version of the manuscript. AD developed the
idea of the study and revised the manuscript. AC, SB, HS, PS, and
OB provided comments and suggestions to improve the quality
of the work. NH and AB drafted the figures and tables. SN and
ZA contributed: contributing to the English editing of the
manuscript. BB and NS: the corresponding authors of the
manuscript, contributing to supporting and also supervising
the manuscript. All authors contributed to the article and
approved the submitted version.ACKNOWLEDGMENTS
We thank Bianca Tino for language revision.REFERENCES
1. Guan Y, Zheng BJ, He YQ, Liu XL, Zhuang ZX, Cheung CL, et al. Isolation
and characterization of viruses related to the SARS coronavirus fromanimals
in southern China. Science (2003) 302:276–8. doi: 10.1126/science.1087139
2. Gretebeck LM, Subbarao K. Animal models for SARS and MERS
coronaviruses. Curr OpinVirol (2015) 13:123–9. doi: 10.1016/j.coviro.
2015.06.009
3. Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic
Comparison of Two Animal-to-Human Transmitted Human
Coronaviruses:SARS-CoV-2 and SARS-CoV. Viruses (2020) 12:244.
doi: 10.1101/2020.04.06.026476
4. Almazán F, Sola I, Zuñiga S, Marquez-Jurado S, Morales L, Becares M, et al.
Coronavirus reverse genetic systems: infectious clones and replicons. Virus
Res (2014) 189:262–70. doi: 10.1016/j.virusres.2014.05.026
5. Masters PS. The molecular biology of coronaviruses. Adv Virus Res (2006)
66:193–292. doi: 10.1016/S0065-3527(06)66005-3
6. Zeng Z-Q, Chen D-H, Tan W-P, Qiu S-Y, Xu D, Liang H-X, et al.
Epidemiology and clinical characteristics of human coronaviruses OC43,
229E, NL63, and HKU1: a study of hospitalized children with acute
respiratory tract infection in Guangzhou, China. Eur J Clin Microbiol
Infect Dis (2018) 37:363–9. doi: 10.1007/s10096-017-3144-z
7. Zhou LX, Tan JJ, Wu M, Luo HT, Yu TO, Kang P, et al. The first case of
severe acute respiratory syndrome in Foshan. Zhonghua Jie He He Hu Xi Za
Zhi (2003) 26:598–601.
8. Rabenau HF, Cinatl J, Morgenstern B, Bauer G, Preiser W, Doerr HW.
Stability and inactivation of SARS coronavirus. Med Microbiol Immunol
(2005) 194:1–6. doi: 10.1007/s00430-004-0219-0
9. De Clercq E. Potential antivirals and antiviral strategies against SARS
coronavirusinfections. Expert Rev Anti-Infective Ther (2006) 4:291–302.
doi: 10.1586/14787210.4.2.291
10. Tong TR. SARS coronavirus anti-infectives. Recent PatentsAnti-Infective
Drug Discov (2006) 1:297–308. doi: 10.2174/157489106778777637
11. Ramadan N, Shaib H. Middle East respiratory syndrome coronavirus (MERS-
CoV): A review. Germs (2019) 9:35–42. doi: 10.18683/germs.2019.1155
12. De Wit E, Van Doremalen N, Falzarano D, Munster VJ. SARS and MERS:
recent insights into emerging coronaviruses.Nat Rev Microbiol (2016)
14:523–34. doi: 10.1038/nrmicro.2016.81
13. Organization WH. Rolling updates on coronavirus disease (COVID-19)
(2020). Available at: https://www.who.int/emergencies/diseases/novel-
coronavirus-2019/events-as-they-happen (Accessed 11 March 2020).
14. Hemmat N, Derakhshani A, Bannazadeh Baghi H, Silvestris N, Baradaran B,
De Summa S. Neutrophils, Crucial, or Harmful Immune Cells Involved in
Coronavirus Infection: ABioinformatics Study. Front Genet (2020) 11:641.
doi: 10.3389/fgene.2020.0064115. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on
current evidence. J Med Virol (2020) 92:548–51. doi: 10.1002/jmv.25722
16. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, Hashem
AM, et al. Evidence for camel-to-human transmission of MERS
coronavirus.N Engl J Med (2014) 370:2499–505. doi: 10.1056/NEJM
oa1401505
17. Woodward A. Both the new coronavirus and SARS outbreaks likely started in
Chinese wet markets. Photos show what the markets look like [Online].
(2020). Available: https://www.businessinsider.com/wuhan-coronavirus-
chinese-wet-market-photos-2020-1. [Accessed].
18. Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19,
SARS and MERS: are they closely related? Clin Microbiol Infect (2020) 26
(6):729–34. doi: 10.1016/j.cmi.2020.03.026
19. Shi Z, Hu Z. Areview of studies on animal reservoirs of the SARS
coronavirus. VirusRes (2008) 133:74–87. doi: 10.1016/j.virusres.2007.03.012
20. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal
origin of SARS-CoV-2. Nat Med (2020) 26:450–2. doi: 10.1038/s41591-020-
0820-9
21. Malaiyan J, Arumugam S, Mohan K, Gomathi Radhakrishnan G. An update
on the origin of SARS-CoV-2: Despite closest identity, bat (RaTG13) and
pangolin derived coronaviruses varied in the critical binding site and O-
linked glycan residues. J Med Virol (2020) 1–7. doi: 10.1002/jmv.26261
22. Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the
Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human
Coronavirus Outbreaks. Pathog (Basel Switzerland) (2020) 9:E186.
doi: 10.3390/pathogens9030186
23. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and coronavirusdisease-2019
(COVID-19): The epidemic and the challenges. Int J Antimicrob Agents
(2020) 55:105924. doi: 10.1016/j.ijantimicag.2020.105924
24. Altschul SF, GishW, Miller W, Myers EW, Lipman DJ. Basic local alignment
search tool. J Mol Biol (1990) 215(3):403–10. doi: 10.1016/S0022-2836(05)
80360-2
25. Saitou N, Nei MJMBEvolution. The neighbor-joining method: a newmethod
for reconstructing phylogenetic trees. Mol Biol Evol (1987) 4:406–25. doi:
10.1093/oxfordjournals.molbev.a040454
26. Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies
by using the neighbor-joining method. Proc Natl Acad Sci U S A (2004) 101
(30):11030–5. doi: 10.1073/pnas.0404206101
27. Kumar S, Stecher G, Li M, Knyaz C, Tamura KJMBEvolution. MEGA X:
molecular evolutionary genetics analysis across computing platforms. Mol
Biol Evol (2018) 35(6):1547–9. doi: 10.1093/molbev/msy096
28. Tahir Ul Qamar M, Alqahtani SM, Alamri MA, Chen L-L. Structural basis of
SARS-CoV-2 3CLpro and anti-COVID-19 drug discovery from medicinal
plants. J Pharm Anal (2020) 10(4):313–9. doi: 10.1016/j.jpha.2020.03.009October 2020 | Volume 10 | Article 572329
Kooshkaki et al. COVID-19: Novel Management Approaches and Treatments29. Neuman BW, Buchmeier MJ. Supramolecular Architecture of the
Coronavirus Particle. Adv Virus Res (2016) 96:1–27. doi: 10.1016/bs.aivir.
2016.08.005
30. Mansoori B, Mohammadi A, Goldar S. Silencing of high mobility group
isoform IC (HMGI-C) enhances paclitaxelchemosensitivity in breast
adenocarcinoma cells (MDA-MB-468). Adv Pharm Bull (2016) 6:171.
doi: 10.15171/apb.2016.024
31. Mcbride R, Fielding BC. The role of severe acute respiratory syndrome
(SARS)-coronavirus accessory proteins in virus pathogenesis. Viruses (2012)
4:2902–23. doi: 10.3390/v4112902
32. Walls AC, Park Y-J, Tortorici MA, Wall A, Mcguire AT, Veesler D.
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike
Glycoprotein. Cell (2020) 181:281–292.e286. doi: 10.1016/j.cell.2020.02.058
33. Belouzard S, Millet J, Licitra B, Whittaker G. Mechanisms of Coronavirus
Cell Entry Mediated by the Viral Spike Protein. Viruses (2012) 4:1011–33.
doi: 10.3390/v4061011
34. Shang J, Wan Y, Liu C, Yount B, Gully K, Yang Y, et al. Structure of mouse
coronavirus spike protein complexed with receptor revealsmechanism for
viral entry. PLoS Pathog (2020) 16:e1008392. doi: 10.1371/journal.
ppat.1008392
35. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and
immune responses. J Med Virol (2020) 92:424–32. doi: 10.1002/jmv.25685
36. Lin L, Lu L, Cao W, Li T. Hypothesis for potential pathogenesis of SARS-
CoV-2 infection-a review of immune changes in patients with viral
pneumonia. Emerg Microbes Infect (2020) 9:727–32. doi: 10.1080/
22221751.2020.1746199
37. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of
peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect
Dis (2020) 221(11):1762–9. doi: 10.1093/infdis/jiaa150
38. Mehta P, Mcauley DF, BrownM, Sanchez E, Tattersall RS, Manson JJ. COVID-
19: consider cytokine storm syndromes and immunosuppression. Lancet (2020)
395:1033–4. doi: 10.1016/S0140-6736(20)30628-0
39. Ramanathan K, Antognini D, Combes A, Paden M, Zakhary B, Ogino M,
et al. Planning and provision of ECMO services for severe ARDS during the
COVID-19 pandemicand other outbreaks of emerging infectious diseases.
Lancet Respir Med (2020) 8(5):518–26. doi: 10.1016/S2213-2600(20)30121-1
40. Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F, et al.
COVID-19 diagnosis and management: a comprehensive review. J Internal
Med 288(2):192–206. doi: 10.1111/joim.13091
41. Zhuang Z, Zhao S, Lin Q, Cao P, Lou Y, Yang L, et al. Preliminary estimates
of the reproduction number of the coronavirus disease(COVID-19)
outbreak in Republic of Korea and Italy by 5 March 2020. Int J Infect Dis
(2020) 95:308–10. doi: 10.1016/j.ijid.2020.04.044
42. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and
Multiorgan Response. Curr Problems Cardiol (2020) 45:100618–8.
doi: 10.1016/j.cpcardiol.2020.100618
43. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system
involvement after infection with COVID-19 and other coronaviruses. Brain
Behav Immun (2020) 87:18–22. doi: 10.1016/j.bbi.2020.03.031
44. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic
Manifestations of Hospitalized Patients With Coronavirus Disease 2019
inWuhan, China. JAMA Neurol (2020) 77:683–90. doi: 10.1001/
jamaneurol.2020.1127
45. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al.
Neurologic Features in Severe SARS-CoV-2 Infection. N Engl J Med (2020)
382:2268–70. doi: 10.1056/NEJMc2008597
46. Tan C, Huang Y, Shi F, Tan K, Ma Q, Chen Y, et al. C-reactive protein
correlates with computed tomographic findings and predicts severe COVID-
19 early. J Med Virol n/a (2020) 92(7):856–62. doi: 10.1002/jmv.25871
47. Lu X, Whitaker B, Sakthivel SKK, Kamili S, Rose LE, Lowe L, et al. Real-time
reverse transcription-PCR assay panel for Middle East respiratory syndrome
coronavirus. J Clin Microbiol (2014) 52:67–75. doi: 10.1128/JCM.02533-13
48. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. 2019 novel
coronavirus patients’ clinical characteristics, discharge rate and fatality rate
of meta-analysis. J Med Virol (2020) 92(6):577–83. doi: 10.1002/jmv.25757
49. Kralik P, Ricchi M. ABasic Guide to Real Time PCR in Microbial
Diagnostics: Definitions, Parameters, andEverything. Front Microbiol
(2017) 8:108–8. doi: 10.3389/fmicb.2017.00108Frontiers in Oncology | www.frontiersin.org 1450. Ye Z, Zhang Y, Wang Y, Huang Z, Song B. Chest CT manifestations of new
coronavirus disease 2019 (COVID-19): a pictorial review. Eur Radiol (2020)
30(8):4381–9. doi: 10.1007/s00330-020-06801-0
51. Xu B, Xing Y, Peng J, Zheng Z, Tang W, Sun Y, et al. Chest CT for detecting
COVID-19: a systematic review and meta-analysis of diagnosticaccuracy.
Eur Radiol (2020) 30(10):5720–7. doi: 10.21203/rs.3.rs-20481/v1
52. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT
and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) inChina: A
Report of 1014 Cases. Radiology (2020) 296(2):E32–Ee40. doi: 10.1148/
radiol.2020200642
53. Imai K, Tabata S, Ikeda M, Noguchi S, Kitagawa Y, Matuoka M, et al.
Clinical evaluation of an immunochromatographic IgM/IgG antibody assay
and chestcomputed tomography for the diagnosis of COVID-19. J Clin Virol
(2020) 128:104393. doi: 10.1016/j.jcv.2020.104393
54. Udugama B, Kadhiresan P, Kozlowski HN, Malekjahani A, Osborne M, Li
VYC, et al. Diagnosing COVID-19: The Disease and Tools for Detection.
ACS nano (2020) 14:3822–35. doi: 10.1021/acsnano.0c02624
55. Xie X, Zhong Z, Zhao W, Zheng C, Wang F, Liu J. Chest CT for Typical
2019-nCoV Pneumonia: Relationship to Negative RT-PCR Testing.
Radiology (2020) 296(2):E41–E5. doi: 10.1080/22221751.2019.1624482
56. Inui S, Fujikawa A, Jitsu M, Kunishima N, Watanabe S, Suzuki Y, et al. Chest
CT Findings in Cases from the Cruise Ship “Diamond Princess” with
mCoronavirus Disease 2019 (COVID-19). J Thorac Imaging (2020) 2(2):
e200110. doi: 10.1148/ryct.2020204002
57. Long Q-X, Tang X-J, Shi Q-L, Li Q, Deng H-J, Yuan J, et al. Clinical and
immunological assessment of asymptomatic SARS-CoV-2 infections. Nat
Med (2020) 26(8):1200–4. doi: 10.1038/s41591-020-0965-6
58. Long Q-X, Liu B-Z, Deng H-J, Wu G-C, Deng K, Chen Y-K, et al. Antibody
responses to SARS-CoV-2 in patients with COVID-19. Nat Med (2020) 26
(6):845–8.
59. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-
CoV-2. JAMA (2020) 323(22):2249–51. doi: 10.1001/jama.2020.8259
60. Guo L, Ren L, Yang S, Xiao M, Chang D, Yang F, et al. Profiling Early
Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19).
Clin Infect Dis (2020) 71(15):778–85. doi: 10.1093/cid/ciaa310
61. Fda. Emergency Use Authorization (2020). Available at: https://www.fda.gov/
emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-
framework/emergency-use-authorization (Accessed 2020/8/3).
62. Karimi-Zarchi M, Neamatzadeh H, Dastgheib SA, Abbasi H, Mirjalili SR,
Behforouz A, et al. Vertical Transmission of Coronavirus Disease 19
(COVID-19) from Infected Pregnant Mothers to Neonates: A Review.
Fetal Pediatr Pathol (2020) 39(3):246–50. doi: 10.1080/15513815.
2020.1747120
63. Liu H, Liu F, Li J, Zhang T, Wang D, Lan W. Clinical and CT imaging
features of the COVID-19 pneumonia: Focus on pregnant women and
children. J Infect (2020) 80:e7–e13. doi: 10.2139/ssrn.3546094
64. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ.
Coronavirus Disease 2019 (COVID-19) and pregnancy: what obstetricians
need to know. Am J Obstet Gynecol (2020) 222:415–26.
65. Rasmussen SA, Smulian JC, Lednicky JA, Wen TS, Jamieson DJ.
Coronavirus Disease 2019 (COVID-19) and Pregnancy: What
obstetricians need to know. Am J Obstet Gynecol (2020) 222(5):415–26.
doi: 10.1016/j.ajog.2020.02.017
66. Schwartz DA. An Analysis of 38 Pregnant Women with COVID-19, Their
Newborn Infants, and Maternal-Fetal Transmission of SARS-CoV-2:
Maternal Coronavirus Infections and Pregnancy Outcomes. Arch Pathol
Lab Med (2020). doi: 10.5858/arpa.2020-0901-SA
67. Schwartz DA, Graham AL. Potential Maternal and Infant Outcomes from
(Wuhan) Coronavirus 2019-nCoV InfectingPregnant Women: Lessons from
SARS, MERS, and Other Human Coronavirus Infections. Viruses (2020)
12:194. doi: 10.3390/v12020194
68. Zeng LK, Tao XW, Yuan WH, Wang J, Liu X, Liu ZS. [First case of neonate
infected with novel coronavirus pneumonia in China]. Zhonghua Er Ke Za
Zhi (2020) 58:E009.
69. Saini KS, De Las Heras B, De Castro J, Venkitaraman R, Poelman M,
Srinivasan G, et al. Effect of the COVID-19 pandemic on cancer treatment
and research. Lancet Haematol (2020) 7:e432–5. doi: 10.1016/S2352-3026
(20)30123-XOctober 2020 | Volume 10 | Article 572329
Kooshkaki et al. COVID-19: Novel Management Approaches and Treatments70. Silvestris N, Moschetta A, Paradiso A, Delvino A. COVID-19 Pandemic and
the Crisis of Health Systems: The Experience of the ApuliaCancer Network
and of the Comprehensive Cancer Center Istituto Tumori “Giovanni Paolo
II” of Bari. Int J Environ Res Public Health (2020) 17:2763. doi: 10.1186/
s13046-020-01614-x
71. Zhang R, Li Y, Pan B, Li Y, Liu A, Li X. Increased expression of hub gene
CXCL10 in peripheral blood mononuclear cells ofpatients with systemic
lupus erythematosus. Exp Ther Med (2019) 18:4067–75. doi: 10.3892/
etm.2019.8013
72. Masumi U, Renato M, Paul CH, Terry M, Jennie RC, Tracy LW, et al.
Managing Cancer Care During the COVID-19 Pandemic: Agility and
Collaboration Toward a Common Goal. J Natl Compr Cancer Netw J Natl
Compr Canc Netw (2020) 18:366–9.
73. Shankar A, Saini D, Roy S, Mosavi Jarrahi A, Chakraborty A, Bharti SJ, et al.
Cancer Care Delivery Challenges Amidst Coronavirus Disease - 19
(COVID-19) Outbreak:Specific Precautions for Cancer Patients and
Cancer Care Providers to Prevent Spread. Asian Pac J Cancer Prev (2020)
21:569–73. doi: 10.31557/APJCP.2020.21.3.569
74. Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship
between waiting time for radiotherapy and clinical outcomes: asystematic
review of the literature. Radiother Oncol (2008) 87:3–16. doi: 10.1016/
j.radonc.2007.11.016
75. Bersanelli M. Controversies about COVID-19 and anticancer treatment with
immune checkpoint inhibitors. Immunotherapy (2020) 0:imt–2020-0067.
76. Choi J, Lee SY. Clinical Characteristics and Treatment of Immune-Related
Adverse Events of ImmuneCheckpoint Inhibitors. Immune Netw (2020)20:
e9. doi: 10.4110/in.2020.20.e9
77. Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic
Effects Associated With Immune Checkpoint Inhibitors: A Systematic
Reviewand Meta-analysis. JAMA Oncol (2018)4:1721–8. doi: 10.1001/
jamaoncol.2018.3923
78. Ye Q, Wang B, Mao J. Thepathogenesis and treatment of the `Cytokine
Storm ’ in COVID-19. JInfect (2020) 80:607–13. doi: 10.1016/
j.jinf.2020.03.037
79. Brunetti O, Derakhshani A, Baradaran B, Galvano A, Russo A, Silvestris N.
COVID-19 infection in cancer patients: how can oncologists deal with these
patients? Front Oncol (2020) 10:734. doi: 10.3389/fonc.2020.00734
80. Silvestris N, Apolone G, Botti G, Ciliberto G, Costantini M, De Paoli P, et al.
A moonshot approach toward the management of cancer patients in the
COVID-19 time:what have we learned and what could the Italian network of
cancer centers (Alliance Against Cancer, ACC) do after the pandemic wave?
J Exp Clin Cancer Res (2020) 39:1–4. doi: 10.3390/ijerph17082763
81. Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary
principle: prioritizing treatment during aglobal pandemic. Nat Rev Clin
Oncol (2020) 17(5):268–70. doi: 10.1038/s41571-020-0362-6
82. Salako O, Okunade K, Allsop M, Habeebu M, Toye M, Oluyede G, et al.
Upheaval in cancer care during the COVID-19 outbreak. Ecancermedicalscience
(2020) 14:ed97–7. doi: 10.3332/ecancer.2020.ed97
83. Soran A, Gimbel M, Diego E. Breast Cancer Diagnosis, Treatment and
Follow-Up During COVID-19Pandemic. Eur J Breast Health (2020) 16:86–
8. doi: 10.5152/ejbh.2020.240320
84. Yu GY, Lou Z, Zhang W. [Several suggestion of operation for colorectal
cancer under the outbreak of Corona Virus Disease 19 in China]. Zhonghua
Wei Chang Wai Ke Za Zhi (2020) 23:9–11.
85. Bartlett DL, Howe JR, Chang G, Crago A, Hogg M, Karakousis G, et al.
Management of Cancer Surgery Cases During the COVID-19 Pandemic:
Considerations. Ann Surg Oncol (2020) 27(6):1717–20. doi: 10.1245/s10434-
020-08461-2
86. Zhao Z, Bai H, Duan J, Wang J. Recommendations of individualized medical
treatment and common adverse eventsmanagement for lung cancer patients
during the outbreak of COVID-19 epidemic. Thorac Cancer (2020) 11
(6):1752–7. doi: 10.1111/1759-7714.13424
87. Topf MC, Shenson JA, Holsinger FC, Wald SH, Cianfichi LJ, Rosenthal EL,
et al. A Framework for Prioritizing Head and Neck Surgery during the
COVID-19Pandemic. Head Neck (2020). doi: 10.1002/hed.26184
88. Dario Mandato V, Aguzzoli L. Management of ovarian cancer during the
COVID-19 pandemic. Int J Gynaecol Obstet (2020). doi: 10.1002/ijgo.13167Frontiers in Oncology | www.frontiersin.org 1589. Akladios C, Azais H, Ballester M, Bendifallah S, Bolze PA, Bourdel N, et al.
[Guidelines for surgical management of gynaecological cancer during
pandemic COVID-19 period - FRANCOGYN group for the CNGOF].
Gynecol Obstet Fertil Senol (2020).
90. Ramirez PT, Chiva L, Eriksson AGZ, Frumovitz M, Fagotti A, Gonzalez
Martin A, et al. COVID-19 Global Pandemic: Options for Management of
GynecologicCancers. Int J Gynecol Cancer (2020). doi: 10.1136/ijgc-2020-
001419
91. Wilder-Smith A, Chiew CJ, Lee VJ. Can we contain the COVID-19 outbreak
with the same measures as for SARS? Lancet Infect Dis (2020) 20(5):e102–e7.
doi: 10.1016/s1473-3099(20)30129-8
92. Turner RB, Felton A, Kosak K, Kelsey DK, Meschievitz CK. Prevention of
experimental coronavirus colds with intranasal alpha-2binterferon. J Infect
Dis (1986) 154:443–7. doi: 10.1093/infdis/154.3.443
93. Pei J, Sekellick MJ, Marcus PI, Choi IS, Collisson EW. Chicken interferon
type I inhibits infectious bronchitis virus replication andassociated
respiratory illness. J Interferon Cytokine Res (2001) 21:1071–7. doi: 10.1089/
107999001317205204
94. Morgenstern B, Michaelis M, Baer PC, Doerr HW, CinatlJJr. Ribavirin
andinterferon-beta synergistically inhibit SARS-associated coronavirus
replication in animal and human cell lines. Biochem Biophys Res Commun
(2005) 326:905–8. doi: 10.1016/j.bbrc.2004.11.128
95. Park A, Iwasaki A. Type I and Type III Interferons - Induction, Signaling,
Evasion, and Application to Combat COVID-19. Cell Host Microbe (2020)
27:870–8. doi: 10.1016/j.chom.2020.05.008
96. Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1
interferons as a potential treatment against COVID-19. Antiviral Res (2020)
178:104791–1. doi: 10.1016/j.antiviral.2020.104791
97. Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral
activities of type I interferons to SARS-CoV-2 infection. Antiviral Res
(2020) 179:104811–1. doi: 10.1016/j.antiviral.2020.104811
98. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW.
Treatment of SARS with human interferons. Lancet (2003) 362:293–4.
doi: 10.1016/S0140-6736(03)13973-6
99. Zhou Q, Chen V, Shannon CP,Wei X-S, Xiang X,Wang X, et al. Interferon-a2b
Treatment for COVID-19. Front Immunol (2020) 11:1061. doi: 10.3389/
fimmu.2020.01061
100. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al.
Comparative therapeutic efficacy of remdesivir and combination lopinavir,
ritonavir,and interferon beta against MERS-CoV. Nat Commun (2020)
11:222. doi: 10.1038/s41467-019-13940-6
101. Nile SH, Nile A, Qiu J, Li L, Jia X, Kai G. COVID-19: Pathogenesis, cytokine
storm and therapeutic potential ofinterferons. Cytokine Growth Factor Rev
(2020) 53:66–70. doi: 10.1016/j.cytogfr.2020.05.002
102. Jolles S, Sewell WAC, Misbah SA. Clinical uses of intravenous
immunoglobulin. Clin ExpImmunol (2005) 142:1–11. doi: 10.1111/j.1365-
2249.2005.02834.x
103. Cao W, Liu X, Bai T, Fan H, Hong K, Song H, et al. High-Dose Intravenous
Immunoglobulin as a Therapeutic Option for DeterioratingPatients With
Coronavirus Disease 2019. Open Forum Infect Dis (2020) 7:ofaa102.
doi: 10.1093/ofid/ofaa102
104. Xie Y, Cao S, Dong H, Li Q, Chen E, Zhang W, et al. Effect of regular
intravenous immunoglobulin therapy on prognosis of severe pneumonia in
patients with COVID-19. J Infect (2020) 81(2):318–56. doi: 10.1016/
j.jinf.2020.03.044
105. Lanza M, Polistina GE, Imitazione P, Annunziata A, Di Spirito V, Novella C,
et al. Successful intravenous immunoglobulin treatment in severe COVID-19
pneumonia. IDCases (2020) 21:e00794. doi: 10.1016/j.idcr.2020.e00794
106. Jawhara S. Could Intravenous Immunoglobulin Collected from Recovered
Coronavirus PatientsProtect against COVID-19 and Strengthen the Immune
System of New Patients? Int J Mol Sci (2020) 21:2272. doi: 10.3390/
ijms21072272
107. Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory
distress syndrome in critically ill patients with severe acuterespiratory
syndrome. JAMA (2003) 290:374–80. doi: 10.1001/jama.290.3.374
108. Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS, Mcdonald DR.
Immunoglobulins in the treatment of COVID-19 infection: ProceedOctober 2020 | Volume 10 | Article 572329
Kooshkaki et al. COVID-19: Novel Management Approaches and Treatmentswithcaution! Clin Immunol (Orlando Fla) (2020) 216:108459–9.
doi: 10.1016/j.clim.2020.108459
109. Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB.
Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory
Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus
Fusion. J Virol (2016) 90:8924–33. doi: 10.1128/JVI.01429-16
110. Khatri A, Wang J, Pendergast AM. Multifunctional Abl kinases in health and
disease. J Cell Sci (2016) 129:9–16. doi: 10.1242/jcs.175521
111. Nabavi SF, Habtemariam S, Clementi E, Berindan-Neagoe I, Cismaru CA,
Rasekhian M, et al. Lessons learned from SARS-CoV and MERS-CoV: FDA-
approved Abelson tyrosine-proteinkinase 2 inhibitors may help us combat
SARS-CoV-2. Arch Med Sci AMS (2020) 16:519–21. doi: 10.5114/
aoms.2020.94504
112. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, ShenM, Patnaik S, et al.
Remdesivir: A Review of Its Discovery and Development Leading to
Emergency UseAuthorization for Treatment of COVID-19. ACS Cent Sci
(2020) 6:672–83. doi: 10.1021/acscentsci.0c00489
113. Green N, Ott RD, Isaacs RJ, Fang H. Cell-based Assays to Identify Inhibitors
of Viral Disease.Expert Opin Drug Discov (2008) 3:671–6. doi: 10.1517/
17460441.3.6.671
114. Varga A, Lionne C, Roy B. Intracellular Metabolism of Nucleoside/
Nucleotide Analogues: a Bottleneck to ReachActive Drugs on HIV Reverse
Transcriptase. Curr Drug Metab (2016) 17:237–52. doi: 10.2174/1389200217
666151210141903
115. Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al.
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in
rhesusmonkeys. Nature (2016) 531:381–5. doi: 10.1038/nature17180
116. De Wit E, Feldmann F, Cronin J, Jordan R, Okumura A, Thomas T, et al.
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus
macaquemodel of MERS-CoV infection. Proc Natl Acad Sci (2020)
117:6771–6. doi: 10.1073/pnas.1922083117
117. Martinez MA. Compounds with therapeutic potential against novel
respiratory 2019 coronavirus. ACC (2020) 64. doi: 10.1128/AAC.00399-20
118. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and
chloroquine effectively inhibit the recently emerged novel coronavirus,
(2019-nCoV) in vitro. Cell Res (2020) 30:269–71. doi: 10.1038/s41422-020-
0282-0
119. Hurst M, Faulds D. Lopinavir. Drugs (2000)60:1371–9; discussion 1380–
1371. doi: 10.2165/00003495-200060060-00009
120. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with
LPV/r versus LPV/r alone against Corona Virus Disease 2019:aretrospective
cohort study. J Infect (2020) 81(1):e1–5. doi: 10.1016/j.jinf.2020.03.002
121. Padberg S. “2.6 - Anti-infective Agents”. In: C Schaefer, P Peters and RKMiller,
editors. Drugs During Pregnancy and Lactation, 3rd ed. SanDiego: Academic
Press (2015). p.115–76. doi: 10.1016/B978-0-12-408078-2.00007-X
122. Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al. HIV
protease inhibitor nelfinavir inhibits replication of SARS-associated
coronavirus. Biochem Biophys Res Commun (2004) 318(3):719–25.
doi: 10.1016/j.bbrc.2004.04.083
123. Yamamoto N, Matsuyama S, Hoshino T, Yamamoto N. Nelfinavir inhibits
replication of severe acute respiratory syndrome coronavirus 2 in vitro.
boiRxiv (2020). 2020.2004.2006.026476. doi: 10.1101/2020.04.06.026476
124. Te HS, Randall G, Jensen DM. Mechanism of action of ribavirin in the
treatment of chronic hepatitis C. Gastroenterol Hepatol (2007) 3:218–25.
125. Khalid M, Khan B, Al Rabiah F, Alismaili R, Saleemi S, Rehan-Khaliq AM,
et al. Middle Eastern Respiratory Syndrome Corona Virus (MERS CoV): case
reports from atertiary care hospital in Saudi Arabia. Ann Saudi Med (2014)
34:396–400. doi: 10.5144/0256-4947.2014.396
126. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL.
Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res
(2013) 100:446–54. doi: 10.1016/j.antiviral.2013.09.015
127. Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen THT, Rodallec A,
et al. Antiviral efficacy of favipiravir against Ebola virus: A translational study
incynomolgus macaques. PLoS Med (2018) 15:e1002535–e1002535.
doi: 10.1371/journal.pmed.1002535
128. Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-
threatening RNA virusinfections. Pharmacol Ther (2020) 209:107512–2.
doi: 10.1016/j.pharmthera.2020.107512Frontiers in Oncology | www.frontiersin.org 16129. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and
chloroquine effectively inhibit the recently emerged novelcoronavirus, (2019-
nCoV) in vitro. Cell Res (2020c) 30:269–71. doi: 10.1038/s41422-020-0282-0
130. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment
with Favipiravir for COVID-19: An Open-Label Control Study. Eng (Beijing)
(2020). doi: 10.1016/j.eng.2020.03.007
131. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus
arbidol for COVID-19: a randomized clinical trial. medRxiv (2020).
doi: 10.1101/2020.03.17.20037432
132. Colson P, Rolain J-M, Lagier J-C, Brouqui P, Raoult D. Chloroquine and
hydroxychloroquine as available weapons to fightCOVID-19. Int J
Antimicrobial Agents (2020) 55(4):105932. doi: 10.1016/j.ijantimicag.
2020.105932
133. Keyaerts E, Vijgen L, Maes P, Neyts J, Ranst MV. In vitro inhibition of severe
acute respiratory syndrome coronavirus bychloroquine. Biochem Biophys Res
Commun (2004) 323:264–8. doi: 10.1016/j.bbrc.2004.08.085
134. Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, Lauridsen L, et al.
Evaluation of immunomodulators, interferons and known in vitro SARS-coV
inhibitorsfor inhibition of SARS-coV replication in BALB/c mice. Antivir
Chem Chemother (2006) 17(5):275–84. doi: 10.1177/095632020601700505
135. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral
effects of chloroquine against coronavirus: what to expect for COVID-19? Int
J Antimicrob Agents (2020) 55(5):105938. doi: 10.1016/j.ijantimicag.
2020.105938
136. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. Asystematic
review on the efficacy and safety of chloroquine for the treatment of COVID-
19. J Crit Care (2020) 57:279–83. doi: 10.1016/j.jcrc.2020.03.005
137. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity
and projection of optimized dosing design ofhydroxychloroquine for the
treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2). Clin Infect Dis (2020) 71(15):732–9. doi: 10.1093/cid/ciaa237
138. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Herv́e
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